9 Sources of evidence considered by the committee

The following documentation and opinion were made available to the committee:

Assessment Report prepared by the NHS Centre for Reviews and Dissemination, University of York. An update of a rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced ovarian cancer, March 2002.

Manufacturer/sponsor submissions:

  • Bristol-Myers Squibb.

Professional/specialist and patient group submissions:

  • CancerBACUP

  • Ovacome

  • Marie Curie Cancer Care

  • MRC Clinical Trials

  • National Cancer Research Institute (formerly UKCCCR)

  • Royal College of Obstetricians and Gynaecologists

External expert and patient advocate submissions:

  • Dr Martin Gore, Consultant Oncologist, Royal Marsden Hospital, London

  • Dr Ganesan, Consultant Medical Oncologist, ICRF Medical Oncology Unit, Oxford Radcliffe Hospital, Oxford

  • Louise Bayne, Chair, Ovacome

  • Martin Ledwick, Senior Cancer Information Specialist, CancerBACUP

  • Joanne Rule, Chief Executive, CancerBACUP